Amendments to the Claims

Please amend Claims 1-8 and 11.

Please add new Claims 14-20.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody competitively inhibits binding of ~~TNF~~ human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

2. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.

3. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of ~~chimeric anti-TNF~~ anti-TNFα chimeric monoclonal antibody cA2.

4. (Currently Amended) A method for treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human at least one anti-TNFα chimeric monoclonal antibody cA2, or a ~~TNF-binding~~ TNFα-binding fragment thereof.

5. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of ~~TNF~~ human TNFα to anti-TNFα chimeric monoclonal antibody cA2.

6. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.

7. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

8. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.

10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.

11. (Currently Amended) A method of treating TNFα-mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNFα-inhibiting amount of an ~~anti-TNF~~ anti-TNFα chimeric antibody, wherein said ~~anti-TNF~~ anti-TNFα chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.

12.-13. (Canceled)

14. (New) The method of Claim 1, wherein said anti-TNFα chimeric antibody is administered to the human by means of parenteral administration.

15. (New) The method of Claim 1, wherein said anti-TNFα chimeric antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.

16. (New) The method of Claim 1, wherein said anti-TNFα chimeric antibody is administered to the human via the lung.

17. (New) The method of Claim 1, wherein said anti-TNFα chimeric antibody is administered to the human orally.

18. (New) The method of Claim 1, wherein said TNFα-inhibiting amount of the anti-TNFα

chimeric antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.

19. (New) The method of Claim 18, wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.

20. (New) The method of Claim 1, further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.